“Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, has secured CE Mark registration for its PromarkerD Immunoassay kit as an IVD medical device (in vitro diagnostic).“
“This is a key market for Proteomics as the company’s business model is centred on the commercialisation of its world-leading test for diabetic kidney disease, PromarkerD.“
Article: Proteomics awarded vital CE Mark registration for PromarkerD
